

Supplementary Information for
Organocatalytic asymmetric direct vinylogous aldol reactions
of γ -crotonolactone with aromatic aldehydes


Sunil V. Pansare* and Eldho K. Paul

Department of Chemistry
Memorial University of Newfoundland
St. John's, Newfoundland, Canada A1B 3X7

General Procedure for the catalytic vinylogous Mukaiyama aldol reaction:

To the catalyst (0.1 mmol, in a 2 mL Reacti-VialTM or a standard 3 mL vial) was added the aldehyde (0.5 mmol) followed by γ -crotonolactone (2-(5H)-furanone) (1mmol) and dichloromethane (0.50 mL). The suspension was stirred for 10 days at room temperature (for catalyst **6**) or kept for 7 days at 0 °C with occasional shaking (for catalyst **5**). The mixture was then diluted with ethyl acetate (1 mL) and aqueous HCl (2N) was added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined extracts were dried (Na₂SO₄), and concentrated. The residue was purified by flash chromatography (CH₂Cl₂/EtOAc, 10/1). The diastereomeric composition (anti/syn) was determined by ¹H NMR analysis of the crude product. The enantiomeric excess was determined by HPLC (Chiralpak AD-H or AS-H column, flow rate 1mL/min, UV detection at 210 or 254 nm) by comparison with reported retention times¹ for compounds **8a-k**, and also by comparison with racemic standards (prepared by using triethylamine as the catalyst) for compounds **8h** and **8i**. The absolute configuration of **8a** was assigned by correlation. Absolute configurations of **8b-k** are assigned by analogy within the series.

5-(Hydroxy (phenyl) methyl) furan-2(5H)-one (8a):




Reaction of γ -crotonolactone (70.0 μ L, 1 mmol) with benzaldehyde (53.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 34.0 mg (35%) of **8a** as a white solid.

IR: 3432, 1728, 1167, 1039, 820 cm⁻¹; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer:** δ 7.43-7.34 (m, 6H, ArH and COCH=CH), 6.19-6.18 (dd, 1H, J = 5.8, 1.9 Hz, COCH=CH), 5.19-5.18 (br m, 1H, CH=CHCH), 5.08-5.10 (br t, 1H, J = 4.1 Hz, ArCHOH), 2.25 (d, 1H, J = 3.8 Hz, OH); **Syn diastereomer:** δ 7.42-7.36 (m, 5H, ArH), 7.16-7.18 (dd, 1H, J = 5.8, 1.5 Hz, COCH=CH), 6.13-6.12 (dd, 1H, J = 5.8, 2 Hz,

COCH=CH), 5.18-5.15 (apparent dt, 1H, $J = 7, 1.5$ Hz, CH=CHCH), 4.72-4.70 (d, 1H, $J = 7.0$ Hz, ArCHOH), 2.78 (s, 1H, OH); MS (APCI pos.): m/z 191.0 (M+1).

HPLC: Chiralpak AS-H, hexanes/2-propanol 90/10, 254 nm, $t_1 = 27.8$ min (major anti), $t_2 = 36.2$ min, (syn), $t_3 = 49.6$ min (syn), $t_4 = 66.8$ min (minor anti). Ee: 97% (anti).

5-(Hydroxy (p-tolyl) methyl) furan-2(5H)-one (8b):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-methylbenzaldehyde (59.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 52.0 mg (51%) of **8b** as a white solid.

IR: 3401, 1736, 1325, 1170, 1102, 1079, 1039, 917, 877 cm^{-1} ; ^1H NMR (500MHz, CDCl_3): **Anti diastereomer**: δ 7.37-7.35 (dd, 1H, $J = 5.8, 1.4$ Hz, COCH=CH), 7.29-7.27 (d, 2H, $J = 8.0$ Hz, ArH), 7.21-7.22 (d, 2H, $J = 8.0$ Hz, ArH, ortho to CH_3), 6.18-6.17 (dd, 1 H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.17-5.15 (m, 1H, CH=CHCH), 5.05-5.03 (br t, 1H, $J = 4.0$ Hz, ArCHOH), 2.37 (3H, CH_3), 2.21-2.22 (d, 1H, $J = 4.0$ Hz, OH), 2.37 (3H, CH_3); **Syn diastereomer**: δ 7.29-7.27 (d, 2H, $J = 8.0$ Hz, ArH), 7.21-7.22 (d, 2H, $J = 8.0$ Hz, ortho to CH_3), 7.16-7.15 (dd, 1H, $J = 5.8, 1.6$ Hz, COCH=CH), 6.13-6.12 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.15-5.17 (m, 1H, CH=CHCH), 4.65-4.67 (dd, 1H, $J = 6.9, 3.0$ Hz, ArCHOH), 2.58 (d, 1H, $J = 3.0$ Hz, OH), 2.37 (3H, CH_3); MS (APCI pos.): m/z 205.0 (M+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 254 nm, $t_1 = 20.0$ min (major anti), $t_2 = 22.2$ min, (minor anti), $t_3 = 26.8$ min (minor syn), $t_4 = 29.0$ min (major syn). Ee: 95% (anti).

5-((4-Bromophenyl) (hydroxy) methyl) furan-2(5H)-one (8c):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-bromobenzaldehyde (93.0 mg, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 83.0 mg (62%) of **8c** as a white solid.

IR: 3343, 1742, 1486, 1399, 1191, 1176, 1095, 1074, 1041, 1008, 917, 880, 831, 808 cm^{-1} ; ^1H NMR (500MHz, CDCl_3): **Anti diastereomer**: δ 7.54-7.55 (d, 2H, $J = 8.4$ Hz, ArH, ortho to Br), 7.31-7.33 (dd, 1H, $J = 5.8, 1.4$ Hz, COCH=CH), 7.28-7.30 (d, 2H, $J = 8.5$ Hz, ArH), 6.20-6.18 (dd, 1 H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.15-5.13 (m, 1H, CH=CHCH), 5.05-5.03 (t, 1H, $J = 4.0$ Hz, ArCHOH), 2.47-2.48 (d, 1H, $J = 4.0$ Hz, OH); **Syn diastereomer**: δ 7.55-7.54 (d, 2H, $J = 8.4$ Hz, ArH, ortho to Br), 7.30-7.28 (d, 2H, $J = 8.4$ Hz), 7.21-7.19 (dd, 1H, $J = 5.8, 1.5$ Hz, COCH=CH), 6.13-6.15 (dd, 1H, $J = 5.8,$

2.0 Hz, COCH=CH), 5.13-5.15 (m, 1H, CH=CHCH), 4.72-4.74 (dd, 1H, $J = 6.7, 3.3$ Hz, ArCHOH), 2.72-2.73 (d, 1H, $J = 3.3$ Hz, OH); MS (APCI pos.): m/z 269.1 (M^+).

HPLC: Chiralpak AD-H, hexanes/2-propanol 88/12, 254 nm, $t_1 = 9.6$ min (major anti), $t_2 = 10.4$ min (minor syn), $t_3 = 10.8$ min (minor anti), $t_4 = 11.6$ min (major syn). Ee: 95% (anti).

5-(Hydroxy (4-methoxyphenyl) methyl) furan-2(5H)-one (8d):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-methoxybenzaldehyde (63.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 39.0 mg (35%) of **8d** as a white solid.

IR: 3357, 1742, 1585, 1510, 1242, 1171, 1101, 1085, 1029, 1008, 877, 827, 814 cm^{-1} ; ^1H NMR (500MHz, CDCl_3): **Anti diastereomer:** δ 7.38-7.39 (dd, 1H, $J = 5.8, 1.5$ Hz, COCH=CH), 7.31-7.32 (d, 2H, $J = 8.7$ Hz, ArH), 6.92-6.94 (d, 2H, $J = 8.7$ Hz, ortho to OCH₃), 6.17-6.18 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.14-5.15 (m, 1H, CH=CHCH), 4.99-5.01 (t, 1H, $J = 4.0$ Hz, ArCHOH), 3.82 (s, 3H, OCH₃), 2.25-2.26 (d, 1H, $J = 4.0$ Hz, OH); **Syn diastereomer:** δ 7.31-7.32 (d, 2H, $J = 8.7$ Hz, ArH), 7.15-7.16 (dd, 1H, $J = 5.8, 1.6$ Hz, COCH=CH), 6.92-6.94 (d, 2H, $J = 8.7$ Hz, ortho to OCH₃), 6.12-6.13 (dd, 1H, $J = 5.8, 2.1$ Hz, COCH=CH), 5.14-5.15 (m, 1H, CH=CHCH), 4.64-4.66 (dd, 1H, $J = 7.1, 3.0$ Hz, ArCHOH), 3.82 (s, 3H, OCH₃), 2.60-2.61 (d, 1H, $J = 3.0$ Hz, OH); MS (APCI pos.): m/z 221.0 ($M+1$), 203.0 ($(M-\text{H}_2\text{O})+1$).

HPLC: Chiralpak AD-H, hexanes/2-propanol 90/10, 254 nm, $t_1 = 15.1$ min (major anti), $t_2 = 17.7$ min (minor anti), $t_3 = 19.0$ min (minor syn), $t_4 = 20.7$ min (major syn). Ee: 97% (anti).

5-(Hydroxy (2-methoxyphenyl) methyl) furan-2(5H)-one (8e):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 2-methoxybenzaldehyde (63.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 64.0 mg (58%) of **8e** as a colorless liquid.

IR: 3418, 1733, 1601, 1491, 1462, 1238, 1160, 1095, 1036, 1022, 816 cm^{-1} ; ^1H NMR (500MHz, CDCl_3): **Anti diastereomer:** δ 7.39-7.40 (dd, 1H, $J = 5.8, 1.0$, COCH=CH), 7.31-7.34 (m, 2H, ArH ortho and para to OCH₃), 7.01-7.04 (t, 1H, $J = 7.5$ Hz, ArH, meta to OCH₃), 6.91-6.93 (d, 1H, $J = 8.3$, ArH), 6.14-6.16 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.37-5.38 (m, 1H, CH=CHCH), 5.30-5.32 (t, 1H, $J = 5.7$ Hz, ArCHOH), 3.89 (s, 3H, OCH₃), 2.81-2.82 (d, 1H, $J = 5.7$ Hz, OH); **Syn diastereomer:** δ 7.31-7.34

(m, 2H, ArH ortho and para to OCH₃), 7.17-7.19 (dd, 1H, *J* = 5.8, 1.1, COCH=CH), 7.01-7.04 (t, 1H, *J* = 7.5 Hz, ArH, meta to OCH₃), 6.91-6.93 (d, 1H, *J* = 8.3, ArH), 6.11-6.13 (dd, 1H, *J* = 5.8, 2.0 Hz, COCH=CH), 5.23-5.24 (br dt, 1H, *J* = 6.6, 1.5, CH=CHCH) 5.01-5.03 (t, 1H, *J* = 5.7 Hz, ArCHOH), 3.85 (s, 3H, OCH₃), 3.05-3.07 (d, 1H, *J* = 5.7 Hz, OH); MS (APCI neg.): *m/z* 219 (M⁺); APCI pos. *m/z* 203.0 ((M-H₂O)+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 85/15, 254, *t*₁ = 8.4 min (major anti), *t*₂ = 11.0 min, (minor anti), *t*₃ = 12.9 min (major syn), *t*₄ = 16.3 min (minor syn). Ee: 96% (anti).

5-(Hydroxy (3-methoxyphenyl) methyl) furan-2(5H)-one (8f):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 3-methoxybenzaldehyde (63.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1mmol) according to the general procedure provided 60.0 mg (54%) of **8f** as a colorless liquid.

IR: 3420, 1735, 1600, 1585, 1489, 1456, 1435, 1256, 1157, 1034, 825 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer:** δ 7.29-7.35 (m, 2H, ArH, COCH=CH), 6.87-6.97 (m, 3H, ArH), 6.16-6.17 (dd, 1H, *J* = 5.8, 2.0 Hz, COCH=CH), 5.15-5.18 (m, 1H, CH=CHCH), 5.07-5.08 (t, 1H, *J* = 4.0 Hz, ArCHOH), 3.82 (s, 3H, OCH₃), 2.73(d, 1H, *J* = 4.0 Hz, OH); **Syn diastereomer:** δ 7.29-7.35 (m, 1H, ArH), 7.17-7.18 (dd, 1H, *J* = 5.8, 1.4 Hz, COCH=CH), 6.87-6.97 (m, 3H, ArH), 6.11-6.12 (dd, 1H, *J* = 5.8, 1.9 Hz, COCH=CH), 5.15-5.18 (m, 1H, CH=CHCH), 4.67-4.69 (dd, 1H, *J* = 7.0, 3.1 Hz, ArCHOH), 3.82 (s, 3H, OCH₃), 2.94 (d, 1H, *J* = 3.1 Hz, OH); MS (APCI pos.): *m/z* 221.0 (M+1), 203.0 ((M-H₂O)+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 90/10, 210 nm, *t*₁ = 14.2 min (major anti), *t*₂ = 18.3 min, (minor anti), *t*₃ = 20.0 min (minor syn), *t*₄ = 21.4 min (major syn). Ee: 96% (anti).

5-((4-Chlorophenyl) (hydroxy) methyl) furan-2(5H)-one (8g):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-chlorobenzaldehyde (70.0 mg, 0.5 mmol) catalyzed by **5** (45.0 mg, 0.1 mmol) according to the general procedure provided 56.0 mg (50%) of **8g** as a white solid.

IR: 3420, 1732, 1491, 1175, 1093, 1078, 1042, 917, 852, 812 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer:** δ 7.31-7.40 (m, 6H, ArH, COCH=CH), 6.19-6.20 (dd, 1H, *J* = 5.8, 2.0 Hz, COCH=CH), 5.13-5.15 (m, 1H, CH=CHCH), 5.04-5.06 (t, 1H, *J* = 4.0 Hz, ArCHOH), 2.37-2.38 (d, 1H, *J* = 4.0 Hz, OH); **Syn diastereomer:** δ 7.31-7.40 (m,

5H, ArH), 7.19-7.20 (dd, 1H, $J = 5.8, 1.5$ Hz, COCH=CH), 6.13-6.15 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.13-5.15 (m, 1H, CH=CHCH), 4.73-4.75 (dd, 1H, $J = 6.8, 3.2$ Hz, ArCHOH), 2.66-2.67 (d, 1H, $J = 3.2$ Hz, OH); MS (APCI pos.): m/z 225.0 (M+1), 207.0 ((M-H₂O)+1).

HPLC: Chiralpak AD-H hexane/2-propanol 95/5, 210 nm, $t_1 = 21.1$ min (major anti), $t_2 = 24.2$ min, (minor anti), $t_3 = 25.9$ min (major syn), $t_4 = 29.4$ min (minor syn). Ee: 94% (anti).

5-(Hydroxy (4-nitrophenyl) methyl) furan-2(5H)-one (8h):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-nitrobenzaldehyde (76.0 mg, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 59.0 mg (50%) of **8h** as a yellow solid.

IR: 3438, 1746, 1515, 1348, 1169, 1103, 1039, 916, 833 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer**: δ 8.25-8.27 (d, 2H, $J = 8.7$ Hz, ArH, ortho to NO₂), 7.59-7.66 (d, $J = 8.7$, 2H, ArH), 7.29-7.30 (dd, 1H, $J = 5.9, 1.6$ Hz, COCH=CH), 6.16-6.17 (dd, 1H, $J = 5.9, 1.8$ Hz, COCH=CH), 5.19-5.21 (m, 2H, CH=CHCH, ArCHOH), 2.76-2.77 (d, 1H, $J = 3.7$ Hz, OH); **Syn diastereomer**: δ 8.28-8.30 (d, 2H, $J = 8.7$ Hz, ArH, ortho to NO₂), 7.59-7.66 (m, 2H, ArH), 7.21 (m, 1H, COCH=CH), 6.23-6.25 (dd, 1H, $J = 5.8, 1.4$ Hz, COCH=CH), 4.98-5.0 (m, 2H, CH=CHCH, ArCHOH), 2.58-2.59 (d, 1H, $J = 3.5$ Hz, OH); MS (APCI pos.): m/z 236.1 (M+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 254 nm, $t_1 = 52.4$ min (major anti), $t_2 = 59.1$ min, (major syn), 70.5 (minor syn). Ee: >99% (anti).

5-((4-(Trifluoromethyl) phenyl) (hydroxy) methyl) furan-2(5H)-one (8i):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 4-trifluoromethylbenzaldehyde (67.0 μ L, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 78.0 mg (60%) of **8i** as a colorless solid.

IR: 3413, 1739, 1322, 1161, 1100, 1065, 1040, 1016, 816 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer**: δ 7.67-7.69 (d, 2H, $J = 8.1$ ArH), 7.54-7.56 (d, 2H, $J = 8.1$), 7.30-7.31 (dd, 1H, $J = 5.8, 1.4$ Hz, COCH=CH), 6.20-6.21 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.14-5.19 (m, 2H, CH=CHCHO, ArCHOH) 2.37-2.38 (d, 1H, $J = 3.9$ Hz, OH); **Syn diastereomer**: δ 7.67-7.69 (d, 2H, $J = 5.7$, ArH), 7.54-7.56 (d, 2H, $J = 5.7$), 7.23-7.25 (dd, 1H, $J = 5.8, 1.5$ Hz, COCH=CH), 6.14-6.15 (dd, 1H, $J = 5.8, 2.0$ Hz,

COCH=CH), 5.14-5.19 (m, 1H, CH=CHCH), 4.91 (m, 1H, ArCHOH), 2.37-2.38 (d, 1H, $J = 3.4$ Hz, OH); MS (APCI pos.): m/z 259.2 (M+1), 241.1 ((M-H₂O)+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 97/3, 254 nm, $t_1 = 28.9$ min (major anti), $t_2 = 32.4$ min, (minor anti). Ee: 95% (anti).

5-(Hydroxy (naphthalen-2-yl) methyl) furan-2(5H)-one (8j):




Reaction of γ -crotonolactone (70.0 μ L, 1mmol) with 2-naphthaldehyde (78.0 mg, 0.5 mmol) catalyzed by **6** (54.7 mg, 0.1 mmol) according to the general procedure provided 88.0 mg (73%) of **8j** as a pale yellow solid.

IR: 3359, 1752, 1731, 1172, 1077, 1041, 824 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer:** δ 7.85-7.90 (m, 4H, ArH), 7.50-7.53 (m, 3H, ArH), 7.35-7.36 (dd, 1H, $J = 5.8, 1.4$ Hz COCH=CH), 6.18-6.20 (dd, 1 H, $J = 5.8, 1.9$ Hz, COCH=CH), 5.26-5.29 (m, 2H, CH=CHCH, ArCHOH), 2.50-2.51 (d, 1H, $J = 3.7$ Hz, OH); **Syn diastereomer:** δ 7.85-7.90 (m, 4H, ArH), 7.50-7.53 (m, 3H, ArH), 7.17-7.19 (dd, 1H, $J = 5.8, 1.6$ Hz, COCH=CH), 6.12-6.14 (dd, 1H, $J = 5.8, 2.0$ Hz, COCH=CH), 5.26-5.29 (m, 2H, CH=CHCH), 4.87-4.89 (dd, 1H, $J = 7.1, 3.1$ Hz, ArCHOH), 2.81 (d, 1H, $J = 3.1$ Hz, OH); MS (APCI pos.): m/z 241.0 (M+1), 223.0 ((M-H₂O)+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 85/15, 254 nm, $t_1 = 9.5$ min (major anti), $t_2 = 11.8$ min, (minor anti), $t_3 = 12.6$ min (major syn), $t_4 = 13.6$ min (minor syn). Ee: 95% (anti).

5-(Cyclohexyl (hydroxy) methyl) furan-2(5H)-one (8k):




Reaction of γ -crotonolactone (70.05 μ L, 1mmol) with cyclohexanecarboxaldehyde (60.17 μ L, 0.5mmol) catalyzed by **5** (45.0 mg, 0.1 mmol) according to the general procedure provided 49.0 mg (50%) of **8k** as a white solid.

IR: 3420, 1747, 1715, 1154, 1112, 1096, 1029, 1004, 870, 845 829 cm^{-1} ; ¹H NMR (500MHz, CDCl₃): **Anti diastereomer:** δ 7.58-7.60 (dd, 1H, $J = 5.8, 1.4$ Hz, COCH=CH), 6.18-6.20 (dd, 1 H, $J = 5.8, 1.9$ Hz, COCH=CH), 5.09-5.10 (dt, 1H, $J = 5.7, 1.6$ Hz, CH=CHCH), 3.60-3.61 (apparent q, 1H, $J = 5.6$ Hz, ArCHOH), 1.96-1.98 (m, 1H, CHCH₂), 1.54-1.82 (m, 4H, CH₂), 1.1-1.33 (m, 6H, CH₂); **Syn diastereomer:** δ 7.44-7.45 (dd, 1H, $J = 5.8, 1.5$ Hz, COCH=CH), 6.18-6.20 (dd, 1 H, $J = 5.8, 1.9$ Hz, COCH=CH), 5.18 (m, 1H, CH=CHCH), 3.45-3.49 (m, 1H, ArCHOH), 1.96-1.98 (m, 1H, CHCH₂), 1.54-1.82 (m, 4H, CH₂), 1.1-1.33 (m, 6H, CH₂); MS (APCI pos.): m/z 197.0 (M+1), 179.1 ((M-H₂O)+1).

HPLC: Chiralpak AD-H, hexanes/2-propanol 95/5, 210 nm, t_1 = 15.4 min (major anti), t_2 = 17.5 min (major syn). Ee: >99% (anti).

Determination of the absolute configuration of **8a**:




To a solution of **8a** in ethylacetate was added Pd/C and the mixture was stirred under an atmosphere of hydrogen for 18 h. Filtration and concentration of the filtrate provided **9** which was dextrorotatory ($[\alpha]_D^{23} = +50.7$ (c 1, $CHCl_3$), 88% ee). The positive rotation indicates that lactone **9** is enantiomeric to the previously reported² $5S,1'R$ isomer ($[\alpha]_D^{25} = -53.3$ (c 0.22, $CHCl_3$) for **9** with 92% ee). Hydrogenolysis of **9** by adaptation of the literature procedure³ provided **10** which was assigned the R configuration on the basis of chiral HPLC retention times⁴ (Chiralcel OD-H, hexanes/2-propanol 80/20, 1 mL/min, 214 nm, $t_S = 5.95$ min, $t_R = 6.74$ min). Lactone **9** is therefore assigned the $5R,1'S$ configuration, and compounds **8a-l** are also assigned the $5R,1'S$ configuration by analogy.

References:


- 1) (a) Y. Yang, K. Zheng, J. Zhao, L. Lin, X. Liu and X. Feng, *J. Org. Chem.* 2010, **75**, 5382; (b) N. Zhu, B. C. Ma, Y. Zhang and W. Wang, *Adv. Synth. Catal.* 2010, **352**, 1291.
- 2) L. Emmanuel and A. Sudalai, *Tetrahedron Lett.* 2008, **49**, 5736.
- 3) H. Ube, N. Shimada and M. Terada, *Angew. Chem., Int. Ed.* 2010, **49**, 1858.
- 4) G. Hoge, *J. Am. Chem. Soc.* 2003, **125**, 10219.

HPLC data for compounds 8a-k


AS-H 90hex 10ipa 254nm 90 min
 EKP-03-47B(2nd Run)




AD-H 95hex5ipa 254nm 60 min
 EKP-03-96B(3rd run)




AD-H 88hex12ipa 254nm 60 min
EKP-03-80B(2nd run)




AD-H 90hex10ipa 254nm 60 min
EKP-03-82B(2nd run)




AD-H 85hex15ipa 254nm 60 min
EKP-03-98B




AD-H 90hex10ipa 210nm 60 min
EKP-03-97B




AD-H 95hex 5ipa 210nm 60 min
EKP-03-77B(4th run)




AD-H 95hex5ipa 254nm 120 min
EKP-03-85B(2nd run)



AD-H 97hex3ipa 254nm 60 min
EKP-03-81B(3rd run)



AD-H 85hex15ipa 254nm 60 min
EKP-03-84B(2nd run)



AD-H 95hex 5ipa 210nm 60 min
EKP-03-91B(2nd run)

